Cardiocomm Solutions Announces Suspension of Trading by the TSX Venture Exchange
Cardiocomm Solutions Announces Suspension of Trading by the TSX Venture Exchange
Toronto, Ontario--(Newsfile Corp. - May 10, 2023) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announces that on May 8, 2023 the TSX Venture Exchange suspended trading in the Company's securities as a result of a Cease Trade Order (the "CTO") issued by the Ontario Securities Commission. The CTO was issued due to the Corporation missing the deadline to file its annual financial statements for the financial year ended December 31, 2022 (the "Financial Statements") and its management's discussion and analysis relating to the Financial Statements (collectively, the "Required Filings") before the prescribed deadline of May 1, 2023 (see the Company's press release dated May 1, 2023 for further details).
安大略省多倫多-(Newsfile Corp.-2023年5月10日)-美國心臟通訊解決方案公司(TSXV：EKG)(“心電聯動“或”公司)宣佈，由於安大略省證券委員會發布的停止交易令(“CTO”)，多倫多證券交易所創業板於2023年5月8日暫停了公司證券的交易。由於公司未能在規定的截止日期2023年5月1日之前提交其截至2022年12月31日的年度財務報表(“財務報表”)以及管理層對財務報表的討論和分析(統稱為“要求提交的財務報表”)(詳情請參閱公司於2023年5月1日發佈的新聞稿)，因此發出了CTO。
The Required Filings are anticipated to be filed by May 30, 2023 or sooner, following which the Company will apply for reinstatement for trading on the TSX Venture Exchange. The Company will provide updates as warranted.
所需的申報檔案預計將於2023年5月30日或更早提交，之後該公司將申請恢復在多倫多證券交易所創業板交易。公司將在保證的情況下提供更新。
To learn more about CardioComm's products and for further updates regarding HeartCheck ECG device integrations please visit the Company's websites at and .
欲瞭解更多有關HearoComm公司產品的資訊，以及有關HeartCheck心電設備集成的進一步更新，請訪問該公司的網站和。
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
關於心通解決方案
心臟通訊解決方案公司的專利和專有技術用於記錄、觀看、分析和存儲心電，用於心臟病患者的診斷和管理。產品通過外部分銷網路和北美銷售團隊銷往世界各地。心臟通信解決方案公司已獲得國際標準化組織13485認證，符合美國食品和藥物管理局的要求，並獲得歐盟(CE標誌)、美國食品和藥物管理局(FDA)和加拿大衛生部(Health Canada)的許可。
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com
欲瞭解更多資訊，請聯繫：
首席執行官艾蒂安·格裡馬
1-877-977-9425轉227
郵箱：egrima@core ocomsoltions.com
郵箱：Investor.Relationship@Hearocomsoltions.com
Forward-looking statements
前瞻性陳述
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
本新聞稿可能包含有關心臟通信解決方案公司的財務狀況、經營和業務結果以及心臟通信解決方案公司與這些專案有關的某些計劃和目標的前瞻性陳述和前瞻性資訊。這些陳述和資訊反映了管理層目前的信念，並以管理層目前掌握的資訊為基礎。就其性質而言，前瞻性陳述和前瞻性資訊涉及風險和不確定性，因為它們與事件有關，並取決於未來發生的情況，而且有許多因素可能導致實際結果和事態發展與這些前瞻性陳述和前瞻性資訊明示或暗示的情況大不相同。
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
在評估這些陳述時，讀者不應過分依賴前瞻性陳述和前瞻性資訊。除適用法律要求外，公司不承擔更新本新聞稿中包含的前瞻性陳述和前瞻性資訊的任何義務，包括但不限於國家文書51-102(持續披露義務).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。